News articles about Ignyta (NASDAQ:RXDX) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ignyta earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1026101045686 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders (finance.yahoo.com)
- Ignyta, Inc. (NASDAQ:RXDX) – Yesterday’s Hot Mover – Nasdaq Journal (press release) (nasdaqjournal.com)
- Analysts Anticipate Ignyta Inc (RXDX) to Post -$0.44 EPS (americanbankingnews.com)
- Ignyta, Inc. (NASDAQ:RXDX) – An Eye on Price to Earnings Ratio – Nasdaq Journal (press release) (nasdaqjournal.com)
Shares of Ignyta (RXDX) opened at $27.00 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34. Ignyta has a 12 month low of $4.60 and a 12 month high of $27.00. The firm has a market capitalization of $1,780.00, a P/E ratio of -9.96 and a beta of 206.07.
RXDX has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $15.00 price target on shares of Ignyta in a research note on Wednesday, September 27th. Zacks Investment Research upgraded Ignyta from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Thursday, October 12th. JPMorgan Chase & Co. restated a “buy” rating and issued a $20.00 price target (up from $18.00) on shares of Ignyta in a research note on Thursday, October 12th. Ladenburg Thalmann Financial Services lifted their price target on Ignyta from $20.25 to $31.00 in a research note on Wednesday, October 18th. Finally, SunTrust Banks initiated coverage on Ignyta in a research note on Monday, November 20th. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $24.33.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.